DOI QR코드

DOI QR Code

Advantages of the single nucleotide polymorphism-based noninvasive prenatal test

  • 투고 : 2015.07.15
  • 심사 : 2015.10.12
  • 발행 : 2015.12.31

초록

Down syndrome screening with cell-free DNA (cfDNA) in the maternal plasma has recently received much attention in the prenatal diagnostic field. Indeed, a large amount of evidence has already accumulated to show that screening tests with cfDNA are more sensitive and specific than conventional maternal serum and/or ultrasound screening. Globally, more than 1,000,000 of these noninvasive prenatal tests (NIPTs) have been performed to date. There are several different methods for NIPTs that are currently commercially available, including shotgun massively parallel sequencing, targeted massively parallel sequencing, and single nucleotide polymorphism (SNP)-based methods. All of these methods have their own advantages and disadvantages. In this review, I will focus specifically on the SNP-based NIPT.

키워드

참고문헌

  1. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370:799-808. https://doi.org/10.1056/NEJMoa1311037
  2. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372:1589-97. https://doi.org/10.1056/NEJMoa1407349
  3. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7. https://doi.org/10.1016/S0140-6736(97)02174-0
  4. Flori E, Doray B, Gautier E, Kohler M, Ernault P, Flori J, et al. Circulating cell-free fetal DNA in maternal serum appears to originate from cytoand syncytio-trophoblastic cells. Case report. Hum Reprod 2004;19:723-4. https://doi.org/10.1093/humrep/deh117
  5. Faas BH, de Ligt J, Janssen I, Eggink AJ, Wijnberger LD, van Vugt JM, et al. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert Opin Biol Ther 2012;12 Suppl 1:S19-26. https://doi.org/10.1517/14712598.2012.670632
  6. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218-24. https://doi.org/10.1086/302205
  7. Nygren AO, Dean J, Jensen TJ, Kruse S, Kwong W, van den Boom D, et al. Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem 2010;56:1627-35. https://doi.org/10.1373/clinchem.2010.146290
  8. Sikora A, Zimmermann BG, Rusterholz C, Birri D, Kolla V, Lapaire O, et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 2010;56:136-8. https://doi.org/10.1373/clinchem.2009.132951
  9. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249-66. https://doi.org/10.1002/uog.14791
  10. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 2014;211:527.e1-527.e17. https://doi.org/10.1016/j.ajog.2014.08.006
  11. Benn P. Non-invasive prenatal testing using cell free dna in maternal plasma: recent developments and future prospects. J Clin Med 2014;3:537-65. https://doi.org/10.3390/jcm3020537
  12. McCullough RM, Almasri EA, Guan X, Geis JA, Hicks SC, Mazloom AR, et al. Non-invasive prenatal chromosomal aneuploidy testing--clinical experience: 100,000 clinical samples. PLoS One 2014;9:e109173. https://doi.org/10.1371/journal.pone.0109173
  13. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 2014;124:210-8. https://doi.org/10.1097/AOG.0000000000000363
  14. Porreco RP, Garite TJ, Maurel K, Marusiak B, Ehrich M, van den Boom D, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol 2014;211:365.e1-12. https://doi.org/10.1016/j.ajog.2014.03.042
  15. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 2013;33:569-74. https://doi.org/10.1002/pd.4123
  16. Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013;33:700-6. https://doi.org/10.1002/pd.4160
  17. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol 2015;45:530-8. https://doi.org/10.1002/uog.14792
  18. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013;26:1180-5. https://doi.org/10.3109/14767058.2013.770464
  19. Zimmermann B, Hill M, Gemelos G, Demko Z, Banjevic M, Baner J, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32:1233-41. https://doi.org/10.1002/pd.3993
  20. Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for noninvasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33:575-9. https://doi.org/10.1002/pd.4103
  21. Hall MP, Hill M, Zimmermann B, Sigurjonsson S, Westemeyer M, Saucier J, et al. Non-invasive prenatal detection of trisomy 13 using a single nucleotide polymorphism- and informatics-based approach. PLoS One 2014;9:e96677. https://doi.org/10.1371/journal.pone.0096677
  22. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013;41:26-32. https://doi.org/10.1002/uog.12331
  23. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened firsttrimester population. Am J Obstet Gynecol 2012;207:374.e1-6. https://doi.org/10.1016/j.ajog.2012.08.033
  24. Chiu RW, Chan KC, Gao Y, Lau VY, Zheng W, Leung TY, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:20458-63. https://doi.org/10.1073/pnas.0810641105
  25. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20. https://doi.org/10.1097/GIM.0b013e3182368a0e
  26. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667-74. https://doi.org/10.1002/pd.4126
  27. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004;32:D493-6. https://doi.org/10.1093/nar/gkh103
  28. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119:890-901. https://doi.org/10.1097/AOG.0b013e31824fb482
  29. Russell LM, Strike P, Browne CE, Jacobs PA. X chromosome loss and ageing. Cytogenet Genome Res 2007;116:181-5. https://doi.org/10.1159/000098184
  30. Wang Y, Chen Y, Tian F, Zhang J, Song Z, Wu Y, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem 2014;60:251-9. https://doi.org/10.1373/clinchem.2013.215145
  31. Snyder MW, Simmons LE, Kitzman JO, Coe BP, Henson JM, Daza RM, et al. Copy-number variation and false positive prenatal aneuploidy screening results. N Engl J Med 2015;372:1639-45. https://doi.org/10.1056/NEJMoa1408408
  32. Curnow KJ, Wilkins-Haug L, Ryan A, Kirkizlar E, Stosic M, Hall MP, et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. Am J Obstet Gynecol 2015;212:79.e1-9. https://doi.org/10.1016/j.ajog.2014.10.012
  33. Nicolaides KH, Syngelaki A, del Mar Gil M, Quezada MS, Zinevich Y. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther 2014;35:212-7. https://doi.org/10.1159/000355655
  34. Simon AL, Su B, Demko Z, Rabinowitz M, Harmon ER, Gross SJ. Detection of complete molar pregnancy by single-nucleotide polymorphism-based non-invasive prenatal testing. Ultrasound Obstet Gynecol 2015;46:506-7. https://doi.org/10.1002/uog.14854
  35. Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, Agrati C, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 2014;16:620-4. https://doi.org/10.1038/gim.2014.3